Skip to main content
Clinical Trials/NCT02072642
NCT02072642
Completed
Not Applicable

Light Therapy in Parkinson's Disease : Effect on Motor Symptoms, Sleep, Circadian Rhythms, and Mood

University Hospital, Strasbourg, France1 site in 1 country44 target enrollmentApril 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson's Disease
Sponsor
University Hospital, Strasbourg, France
Enrollment
44
Locations
1
Primary Endpoint
Global score :Unified Parkinson's Disease Rating Scale (UPDRS) I II III
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Parkinson's disease, a degenerative disorder of the dopaminergic system, combines motor symptoms but also non-motor, such as depression, sleep disorders and circadian rhythms and impaired cognitive functions. Difficulties in balancing the dopaminergic treatment of these patients emphasizes the need to find effective adjuvant therapies. Light therapy (LT) represents one such innovative therapeutic approach. Although light has an obvious to visual pathways within the brain, today it is known to additionally exert non-visual effects throughout the body. Recently our team has shown that non-visual, non-circadian light plays a major role in the regulation of sleep, as well as cognitive brain function in general. The retina, the primary conduit for the transmission of light information is weakened or thinned in Parkinson's patients. The dopamine system is known to enhance the processing of light information and intraocular injection of L-dopa in animal models of Parkinson's disease, can reverse associated motor symptoms. This allows for the possibility that LT would strengthen the dopaminergic tone in the central nervous system. However, to this date its effectiveness for alleviating Parkinson's symptoms has only been suggested by two studies, both poorly controlled. Thus, through the convergence of basic and clinical data, a study examining the effect of LT directly in people Parkinson's disease symptoms, whilst controlling for the effects on sleep, circadian system, mood, and cognitive functioning, is of extreme importance. With this information our hope is to determine if these polymorphisms allow for a predictive model of response to LT treatment.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
May 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital, Strasbourg, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Idiopathic Parkison's Disease, low or moderately severe
  • Hoehn\&Yahr \<4
  • 4 to \< 15 years of evolution·
  • Between 45-75 years old
  • Absence of dementia : MMSE \> 23·
  • No severe depression
  • Stable medication levels during the 5 weeks before inclusion

Exclusion Criteria

  • Secondary or severe Parkinson's disease
  • Ocular pathologies (i.e. retinopathy)
  • Photosensitive medication
  • Antidepressant treatment·
  • Major depression syndrome
  • MMSE \< 23
  • Circadian rhythm problems
  • Sleep apnea syndrome
  • Manifested or acute psychiatric comorbidities
  • Pregnant women

Outcomes

Primary Outcomes

Global score :Unified Parkinson's Disease Rating Scale (UPDRS) I II III

Time Frame: 5 weeks

Study Sites (1)

Loading locations...

Similar Trials